Enanta Pharmaceuticals (FRA:9EP) LT-Debt-to-Total-Asset : 0.16 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Enanta Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.16.

Enanta Pharmaceuticals's long-term debt to total assets ratio increased from Dec. 2023 (0.05) to Dec. 2024 (0.16). It may suggest that Enanta Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Enanta Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Enanta Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals LT-Debt-to-Total-Asset Chart

Enanta Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.06

0.05

0.14

Enanta Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.11	0.12	0.14	0.16

Enanta Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Enanta Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (A: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2024 )	/	Total Assets (A: Sep. 2024 )
	=	48.603	/	339.363
	=	0.14

Enanta Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	53.913	/	332.953
	=	0.16

Enanta Pharmaceuticals (FRA:9EP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Enanta Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Enanta Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (FRA:9EP) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ENTA:USA

Address

4 Kingsbury Avenue, Watertown, MA, USA, 02472

Website

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals Headlines

No Headlines